1Amos AF,McCarty PJ,Zimmet PJ.The rising global burden of diabetes and its complications:estimates and projection to the year 2010[J].Diabet Med,1997,14(Suppl 5):S1-S85.
2UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complication in type 2 diabetes[J].BMJ,1998,317(7160):703-713.
3UK Prospective Diabetes Study Group.Insitute blood glucose control with sulphonyl-ureas or insulin compared with conventional risk of complication in patient with type 2 diabetes(UKPDS 33)[J].Lancet,1998,352(9131):837-853.
5Kasiske BL,O Dennel MP.The zuoker rat model of obesity,insulin resistance,hperlipidemia,and renal injury[J].Hypertension,1992,19(1 suppl):110-115.
6Ravid M,Brosh D,Ravid-Safran D,et al.Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels,mean blood pressure,and hyperglycemia[J].Arch Intern Med,1998,158(9):998-1004.
7Nazimek-Siewniak B,Moczulski D,Grzeszczak W.Risk of macrovascular and microvascular complications in Type 2 diabetes:results of longitudinal study design[J].Diabetes Complications,2002,16(4):271-276.
8Parving HH,Lehnert H,Brochner-Mortensen J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J].N Engl J Med,2001,345(12):870-878.
9Molnar M,Wittmann I,Nagy J.Prevalence,course and risk factors of diabetic nephropathy in type-2 diabetes mellitus[J].Med Sci Monit,2000,6(5):929-936.
10Rachmani R,Levi Z,Slavachevski I,et al.Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with Type 2 diabetes mellitus--a randomized prospective study[J].Diabet Med,2002,19(5):385-392.
